BioMarin (BMRN) Pharmaceutical announced that the Phase 3 PEGASUS trial evaluating Palynziq met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe levels in adolescents aged 12-17 with phenylketonuria compared to diet alone. Safety results were consistent with the known profile of the medicine. Palynziq is the first and only enzyme therapy approved to treat adults with PKU.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin presents studies showing efficacy of Voxzogo, Palynziq
- Strong Growth Potential and Strategic Positioning Make BioMarin Pharmaceutical a Buy Recommendation
- Insider Moves: Semtech, BioMarin, Yum!, Tenaya, Aurinia
- BioMarin Pharmaceutical: Strategic Growth and Pipeline Potential Drive Buy Rating
- BioMarin Expands Board with New Independent Director